Published in N Engl J Med on December 21, 2006
The limitations of risk factors as prognostic tools. N Engl J Med (2006) 5.90
Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA (2009) 5.52
Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet (2008) 5.49
Assessing the value of risk predictions by using risk stratification tables. Ann Intern Med (2008) 5.05
Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation (2011) 4.78
Phenomics: the next challenge. Nat Rev Genet (2010) 4.20
Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol (2013) 3.89
Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med (2010) 3.57
The role of HIV in serious diseases other than AIDS. AIDS (2008) 3.39
Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol (2012) 3.24
Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol (2010) 3.23
Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol (2008) 2.93
Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology (2013) 2.82
Urine neutrophil gelatinase-associated lipocalin moderately predicts acute kidney injury in critically ill adults. J Am Soc Nephrol (2009) 2.77
Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation (2010) 2.32
Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing. J Am Coll Cardiol (2010) 2.32
Association of leukocyte telomere length with circulating biomarkers of the renin-angiotensin-aldosterone system: the Framingham Heart Study. Circulation (2008) 2.22
Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr (2011) 2.21
Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest (2009) 2.17
Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol (2008) 2.14
Association of major and minor ECG abnormalities with coronary heart disease events. JAMA (2012) 2.07
Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation (2009) 2.05
N-terminal pro-B-type natriuretic peptide and stroke risk: the reasons for geographic and racial differences in stroke cohort. Stroke (2014) 1.98
Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation (2012) 1.95
A multi-marker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol (2010) 1.95
Multiple markers of inflammation and weight status: cross-sectional analyses throughout childhood. Pediatrics (2010) 1.90
Gamma' fibrinogen: evaluation of a new assay for study of associations with cardiovascular disease. Clin Chem (2010) 1.80
Inflammation and coagulation markers and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis (2012) 1.79
Aggregate risk score based on markers of inflammation, cell stress, and coagulation is an independent predictor of adverse cardiovascular outcomes. J Am Coll Cardiol (2013) 1.77
Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol (2010) 1.77
Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation (2011) 1.77
Biomarkers of cardiovascular stress and incident chronic kidney disease. Clin Chem (2013) 1.71
Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey. Drug Des Devel Ther (2011) 1.68
Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia (2009) 1.65
Inflammation and cardiovascular events in individuals with and without chronic kidney disease. Kidney Int (2008) 1.64
Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: an observational study of 17,345 persons. PLoS Med (2014) 1.60
Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail (2012) 1.57
Misuse of DeLong test to compare AUCs for nested models. Stat Med (2012) 1.54
Calibrating parametric subject-specific risk estimation. Biometrika (2010) 1.54
Improving global vascular risk prediction with behavioral and anthropometric factors. The multiethnic NOMAS (Northern Manhattan Cohort Study). J Am Coll Cardiol (2009) 1.52
1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death. Mol Syst Biol (2008) 1.51
Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest (2009) 1.50
Identifying important risk factors for survival in patient with systolic heart failure using random survival forests. Circ Cardiovasc Qual Outcomes (2010) 1.48
N-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death risk: the Cardiovascular Health Study. Heart Rhythm (2010) 1.48
Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. Am J Physiol Lung Cell Mol Physiol (2008) 1.46
Depression and Human Immunodeficiency Virus Infection Are Risk Factors for Incident Heart Failure Among Veterans: Veterans Aging Cohort Study. Circulation (2015) 1.43
Obesity and C-reactive protein levels among white, black, and hispanic US adults. Obesity (Silver Spring) (2008) 1.38
Use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injury. Crit Care Med (2011) 1.31
Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. Thromb Haemost (2008) 1.30
Pathway analysis of dilated cardiomyopathy using global proteomic profiling and enrichment maps. Proteomics (2010) 1.29
Endothelial function as a functional expression of cardiovascular risk factors. Biomark Med (2010) 1.25
The treatment of hyperhomocysteinemia. Annu Rev Med (2009) 1.23
Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci (2010) 1.22
The use of high-sensitivity assays for C-reactive protein in clinical practice. Nat Clin Pract Cardiovasc Med (2008) 1.21
Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer (2009) 1.20
Recommendations for lipid testing and reporting by Australian pathology laboratories. Clin Biochem Rev (2007) 1.19
The Framingham Heart Study's impact on global risk assessment. Prog Cardiovasc Dis (2010) 1.16
Renin: friend or foe? Heart (2007) 1.16
Early identification of cardiovascular risk using genomics and proteomics. Nat Rev Cardiol (2010) 1.14
Inflammatory concepts of obesity. Int J Inflam (2011) 1.14
Markers of atherosclerosis and inflammation for prediction of coronary heart disease in older adults. Am J Epidemiol (2010) 1.14
Risk prediction measures for case-cohort and nested case-control designs: an application to cardiovascular disease. Am J Epidemiol (2012) 1.13
Natriuretic peptides in the diagnosis and management of chronic heart failure. Heart Fail Clin (2009) 1.12
TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling. J Mol Cell Cardiol (2008) 1.12
Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem (2012) 1.11
Circulating progenitor cell count for cardiovascular risk stratification: a pooled analysis. PLoS One (2010) 1.09
Estimating the capacity for improvement in risk prediction with a marker. Biostatistics (2008) 1.08
Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. J Am Heart Assoc (2014) 1.08
Analysis of a urinary biomarker panel for incident kidney disease and clinical outcomes. J Am Soc Nephrol (2013) 1.08
Evaluating the clinical utility of a biomarker: a review of methods for estimating health impact. Circulation (2011) 1.07
Early detection of myocardial dysfunction and heart failure. Nat Rev Cardiol (2010) 1.06
Dyslipidemia associated with chronic kidney disease. Open Cardiovasc Med J (2011) 1.06
Amino-terminal fragment of the prohormone brain-type natriuretic peptide in rheumatoid arthritis. Arthritis Rheum (2008) 1.06
Multiple inflammatory biomarkers in relation to cardiovascular events and mortality in the community. Arterioscler Thromb Vasc Biol (2013) 1.05
Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics. Circ Res (2011) 1.04
Assessing the Incremental Role of Novel and Emerging Risk Factors. Curr Cardiovasc Risk Rep (2010) 1.04
A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheumatol (2014) 1.02
Toward new biomarkers of cardiometabolic diseases. Cell Metab (2013) 1.02
Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nat Rev Nephrol (2011) 1.01
Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves. Curr Opin HIV AIDS (2010) 1.01
Redox-induced Src kinase and caveolin-1 signaling in TGF-β1-initiated SMAD2/3 activation and PAI-1 expression. PLoS One (2011) 1.00
Classical and novel biomarkers for cardiovascular risk prediction in the United States. J Epidemiol (2013) 1.00
Assessing risk for development of diabetes in young adults. Ann Fam Med (2007) 1.00
Behavior, nutrition and lifestyle in a comprehensive health and disease paradigm: skills and knowledge for a predictive, preventive and personalized medicine. EPMA J (2012) 1.00
Biomarkers in peripheral arterial disease patients and near- and longer-term mortality. J Vasc Surg (2010) 1.00
Plasma lipid composition and risk of developing cardiovascular disease. PLoS One (2013) 0.99
Clinical and genetic correlates of growth differentiation factor 15 in the community. Clin Chem (2012) 0.99
Prediction of coronary artery calcium progression in individuals with low Framingham Risk Score: the Multi-Ethnic Study of Atherosclerosis. JACC Cardiovasc Imaging (2012) 0.98
Biomarkers of peripheral arterial disease. J Am Coll Cardiol (2010) 0.98
Cardiovascular Disease Risk Assessment: Insights from Framingham. Glob Heart (2013) 0.98
Evaluating subject-level incremental values of new markers for risk classification rule. Lifetime Data Anal (2013) 0.97
Cardiovascular risk. Br J Clin Pharmacol (2012) 0.97
Ascites improves upon [corrected] serum sodium plus [corrected] model for end-stage liver disease (MELD) for predicting mortality in patients with advanced liver disease. Aliment Pharmacol Ther (2009) 0.95
Do serum biomarkers really measure breast cancer? BMC Cancer (2009) 0.95
Smoking-Associated DNA Methylation Biomarkers and Their Predictive Value for All-Cause and Cardiovascular Mortality. Environ Health Perspect (2015) 0.94
10-years experience with the Athero-Express study. Cardiovasc Diagn Ther (2012) 0.93
Multiple biomarkers and risk of clinical and subclinical vascular brain injury: the Framingham Offspring Study. Circulation (2012) 0.93
Metabolomic profiling for identification of novel potential biomarkers in cardiovascular diseases. J Biomed Biotechnol (2011) 0.93
A healthier approach to clinical trials evaluating resveratrol for primary prevention of age‐related diseases in healthy populations. Aging (Albany NY) (2013) 0.93
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med (2008) 57.29
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (2007) 51.70
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98
Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation (2008) 26.42
Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74
Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet (2008) 20.73
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 17.18
Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol (2002) 16.25
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med (2002) 16.23
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA (2007) 15.32
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med (2010) 14.49
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation (2007) 12.79
Obesity and the risk of heart failure. N Engl J Med (2002) 12.58
Metabolite profiles and the risk of developing diabetes. Nat Med (2011) 12.22
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Genome-wide association study of blood pressure and hypertension. Nat Genet (2009) 11.54
Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med (2004) 11.46
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet (2012) 11.32
Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med (2002) 11.20
The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA (2013) 10.43
Long-term trends in the incidence of and survival with heart failure. N Engl J Med (2002) 10.37
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2015) 10.14
The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol (2007) 9.90
Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med (2008) 9.83
Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med (2008) 9.68
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA (2007) 9.68
C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47
Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation (2010) 9.09
Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med (2013) 8.91
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 8.90
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation (2004) 8.80
Incidence of diabetes in youth in the United States. JAMA (2007) 8.70
Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med (2007) 8.59
Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation (2005) 8.54
Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation (2002) 8.49
Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension (2004) 8.27
Application of new cholesterol guidelines to a population-based sample. N Engl J Med (2014) 8.22
2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 7.54
Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol (2003) 7.47
Plasma adiponectin levels and risk of myocardial infarction in men. JAMA (2004) 7.46
Predictors of new-onset kidney disease in a community-based population. JAMA (2004) 7.45
Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease. Circulation (2003) 7.40
C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation (2008) 7.33
Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet (2009) 7.27